Kenvue beats first-quarter estimates amid pending acquisition by Kimberly-Clark

May 7 (Reuters) - Tylenol-maker Kenvue ‌on Thursday ​beat ​Wall Street estimates for first-quarter revenue and profit helped by strong sales in its skin health and beauty ‌brands.

The consumer health company, currently in the midst of ⁠a $40 billion buyout by Kimberly-Clark, expects the deal to close in the ‌second half of the year.

Here ‌are the results:

• Kenvue reported first-quarter adjusted earnings per share of 32 cents per share; analysts on an average expected ​26 cents, according to data complied by LSEG.

• The company reported quarterly net sales of $3.91 billion, an increase of ⁠4.5% from a year earlier and above analysts' estimates of $3.84 billion.

• Net sales at ​its skin health and beauty unit that includes brands like Neutrogena and Aveeno rose 8.4% to $1.06 billion ​for the three months ended March ‌29, helped by strong increase in sales worldwide.

• "We remain confident ... as we accelerate our organization and business ⁠transformation through our new strategic plans and work toward completing our value-creating combination with Kimberly-Clark in the second half of this year,” said ⁠CEO Kirk Perry.

• The company said its restructuring plan is expected to ​result in pre-tax restructuring expenses and other charges, totaling about $250 million this year.

• "Kenvue's time as a public company has been tumultuous … Fundamentals still matter ‌but in the near term will take a backseat to the deal and ongoing litigation headlines ‌which we believe will take time to resolve," said RBC Capital ⁠Markets analyst Nik Modi. He ‌called the results ​bullish for Kimberly-Clark as "Kenvue's fundamentals seem to be stabilizing."

(Reporting by Sneha S K in Bengaluru; Editing by ‌Joyjeet Das)

---

Serious News for Serious Traders! Try StreetInsider.com Premium Free!

---

You May Also Be Interested In

• Is the global equity rally broadening? UBS weighs in
• Why this strategist thinks longer-term outlook for stocks is "unfavorable"
• RenovoRx regains Nasdaq minimum bid price compliance